Study of Irinotecan Administered as a Continuous Infusion and Radiation Therapy for Upper Gastrointestinal Cancers
Pancreatic Cancer, Gastric Cancer, Duodenum Cancer
About this trial
This is an interventional treatment trial for Pancreatic Cancer focused on measuring pancreas, stomach, common bile duct cancer, ampulla of Vater cancer
Eligibility Criteria
Inclusion Criteria: Histologically confirmed neoplasm of the upper gastrointestinal tract (pancreas, stomach, duodenum, common bile duct, ampulla of Vater) or metastatic tumor to the upper abdomen. Eligible patients include patients with locally advanced unresectable tumors, positive surgical margins, local recurrence and resected stage II-III pancreatic, gastric, duodenum, bile duct or ampulla of Vater carcinoma. Performance status SWOG 0-2 Fully recovered from prior surgery or chemotherapy (greater than or equal to 4 weeks). Patients previously treated with 5-FU or gemcitabine may start therapy 2 weeks after the last dose of 5-FU or gemcitabine. Absolute granulocyte count (AGC) > 1500; platelets > 100,000; serum creatinine < 2.0 mg/dl; total bilirubin < 2.0 mg/dl; AST or ALT and alkaline phosphatase < 3 times the upper limit of normal. Prior chemotherapy is allowed. Exclusion Criteria: Prior radiation therapy to the upper abdomen Tumors of the gastroesophageal junction. Other medical, psychological or social circumstances that, in the opinion of the investigator, would prevent participation in the clinical trial Pregnancy.
Sites / Locations
- U.S.C./Norris Cancer Center